EMA/149058/2022

European Medicines Agency decision

P/0123/2022

of 15 April 2022

on the acceptance of a modification of an agreed paediatric investigation plan for tapotoclax (EMEA-002631-PIP01-19-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0123/2022

of 15 April 2022

on the acceptance of a modification of an agreed paediatric investigation plan for tapotoclax (EMEA-002631-PIP01-19-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0331/2020 issued on 24 August 2020,

Having regard to the application submitted by Amgen Europe BV on 18 November 2021 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 25 February 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for tapotoclax, concentrate for solution for infusion, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Amgen Europe BV, Minervum 7061, 4817 ZK - Breda, The Netherlands.

EMA/PDCO/710087/2021

Amsterdam, 25 February 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002631-PIP01-19-M01

Scope of the application

Active substance(s):

Tapotoclax

Condition(s):

Treatment of acute myeloid leukaemia

Pharmaceutical form(s):

Concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Amgen Europe BV

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Amgen Europe BV submitted to the European Medicines Agency on 18 November 2021 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0331/2020 issued on 24 August 2020.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 4 January 2022.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of acute myeloid leukaemia

The waiver applies to:

- the paediatric population from birth to less than 28 days of age;
- concentrate for solution for infusion, intravenous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of acute myeloid leukaemia (AML)

2.1.1. Indication(s) targeted by the PIP

The treatment of first relapse and refractory AML in paediatric patients

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 28 days to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable.
Non-clinical studies	**Study 1** Dose range-finding juvenile toxicity study **Study 2** Definitive juvenile toxicity study
Clinical studies	**Study 3** Open-label, two part study to evaluate safety, tolerability, pharmacokinetics (PK) and establish a recommended Phase 2 combination dose (RP2CD) (Part 1) followed by a randomised (3:1), active controlled part 2, to evaluate safety and efficacy of AMG 176 as add-on to re-induction chemotherapy (fludarabine, cytarabine plus optional G-CSF [FLA(G)]) compared to re-induction

	chemotherapy alone in children from 28 days to less than 18 years of age with relapsed or refractory AML.
Extrapolation, modelling and simulation studies	**Study 4** Use of Population (Pop)/PKPD to inform initial paediatric dosing in clinical studies.
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes